Policy & Regulation
Sun Pharmaceutical announces results from Phase one, multiple ascending-dose study of GL0034 (Utreglutide) at 84th ADA
24 June 2024 -

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), an India-based, global specialty generics company with presence in Innovative products, Generics and Consumer Healthcare products, announced on Saturday that it presented its results from a Phase one, multiple ascending-dose study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034 (Utreglutide) in obese adults in an oral presentation at the 84th Scientific Sessions of the American Diabetes Association (ADA), on 21 June 2024, in Orlando, Florida.

GL0034 (Utreglutide) is a novel differentiated incretin analogue with potent, long-acting agonist activity at the GLP-1 receptor, under evaluation for its potential to provide significant clinical benefits beyond weight loss and gluco-metabolic benefits in individuals with obesity.

The company says that during the study, GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved gluco-metabolic parameters over a four-week treatment period in individuals with obesity, even in the lowest dosing regimen. It demonstrated gluco-metabolic activity and a reduction in lipid levels, including triglycerides, total cholesterol, and non-HDL cholesterol, indicating novel and beneficial impacts on lipid metabolism.

GL0034 is claimed to have demonstrated a favourable tolerability profile, with gastrointestinal (GI) adverse events consistent with those typically seen in the incretin class. The findings indicated the product's potential as a therapeutic option for individuals with obesity, offering not only weight loss, but also improvements in key cardiometabolic biomarkers.